ABSI Stock Analysis: Absci | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.968m USD | 12M Return: 339.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 54.8M
Qual. Beats: -2
Rev. Trend: -88.7%
Qual. Beats: -3
Warnings
Tailwinds
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Absci Corporation is a clinical-stage biopharmaceutical company developing antibody therapeutics, with operations based in the United States. Its pipeline spans inflammatory disease, immuno-oncology, and dermatology indications, including ABS-101 (inflammatory bowel disease, Phase 1), ABS-201 (androgenic alopecia, Phase 1/2a), ABS-301 (immuno-oncology), and ABS-501 (oncology).
The company maintains a collaboration-driven business model, with joint research and development agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle, and AMD. Absci was founded in 2011 and is headquartered in Vancouver, Washington. As a clinical-stage biotech, Absci operates in a capital-intensive sector where development timelines are long, approval outcomes are uncertain, and revenue typically depends on milestone payments and partnerships rather than product sales until products reach the market.
- ABS-201 alopecia Phase 1/2a trial data readout approaches
- AI platform partnership revenue from Oracle and AMD collaborations grows
- Cash burn and share dilution remain critical overhangs
| Net Income: -118.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.50 > 0.02 and ΔFCF/TA -17.32 > 1.0 |
| NWC/Revenue: 6.10k% < 20% (prev 2.67k%; Δ 3.42k% < -1%) |
| CFO/TA -0.50 > 3% & CFO -97.4m > Net Income -118.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (153.0m) vs 12m ago 22.90% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.86% > 50% (prev 2.07%; Δ -1.21% > 0%) |
| Interest Coverage Ratio: -1.06k > 6 (EBIT TTM -118.2m / Interest Expense TTM 112k) |
| A: 0.57 (Total Current Assets 132.0m - Total Current Liabilities 20.0m) / Total Assets 195.6m |
| B: -3.35 (Retained Earnings -654.4m / Total Assets 195.6m) |
| C: -0.55 (EBIT TTM -118.2m / Avg Total Assets 214.0m) |
| D: 7.28 (Book Value of Equity 172.0m / Total Liabilities 23.6m) |
| Altman-Z'' = -3.22 = D |
As of July 08, 2026, the stock is trading at USD 11.33 with a total of 4,104,874 shares traded. Over the past week, the price has changed by -0.18%, over one month by +72.98%, over three months by +288.01% and over the past year by +339.15%.
Current recommended Stop Loss: 10.10 (which is 10.9% or 1.3 ATR below the current price).
Absci has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy ABSI.
- StrongBuy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13 | 14.7% |
P/S = 1072.1306
P/B = 11.4168
Revenue TTM = 1.84m USD
EBIT TTM = -118.2m USD
EBITDA TTM = -106.8m USD
Long Term Debt = 2.15m USD (estimated: total debt 4.42m - short term 2.27m)
Short Term Debt = 2.27m USD (from shortTermDebt, last quarter)
Debt = 8.42m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.00m
Net Debt = -117.3m USD (calculated: Debt 8.42m - CCE 125.7m)
Enterprise Value = 1.85b USD (1.97b + Debt 8.42m - CCE 125.7m)
Interest Coverage Ratio = -1.06k (Ebit TTM -118.2m / Interest Expense TTM 112k)
EV/FCF = -18.79x (Enterprise Value 1.85b / FCF TTM -98.5m)
FCF Yield = -5.32% (FCF TTM -98.5m / Enterprise Value 1.85b)
FCF Margin = -5.37k% (FCF TTM -98.5m / Revenue TTM 1.84m)
Net Margin = -6.45k% (Net Income TTM -118.4m / Revenue TTM 1.84m)
Gross Margin = unknown ((Revenue TTM 1.84m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Tobins Q-Ratio = 9.46 (Enterprise Value 1.85b / Total Assets 195.6m)
Interest Expense / Debt = 1.33% (Interest Expense 112k / Debt 8.42m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -93.4m (EBIT -118.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.59 (Total Current Assets 132.0m / Total Current Liabilities 20.0m)
Debt / Equity = 0.05 (Debt 8.42m / totalStockholderEquity, last quarter 172.0m)
Debt / EBITDA = 1.10 (negative EBITDA) (Net Debt -117.3m / EBITDA -106.8m)
Debt / FCF = 1.19 (negative FCF - burning cash) (Net Debt -117.3m / FCF TTM -98.5m)
Total Stockholder Equity = 186.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.34% (Net Income -118.4m / Total Assets 195.6m)
RoE = -63.58% (Net Income TTM -118.4m / Total Stockholder Equity 186.3m)
RoCE = -62.75% (EBIT -118.2m / Capital Employed (Equity 186.3m + L.T.Debt 2.15m))
RoIC = -52.55% (negative operating profit) (NOPAT -93.4m / Invested Capital 177.7m)
WACC = 13.86% (E(1.97b)/V(1.98b) * Re(13.91%) + D(8.42m)/V(1.98b) * Rd(1.33%) * (1-Tc(0.21)))
Discount Rate = 13.91% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 25.01%
[DCF] Fair Price = unknown (Cash Flow -98.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.89 | # QB: -2
Revenue Correlation: -88.70 | Revenue CAGR: -34.35% | SUE: -1.95 | # QB: -3
EPS current Quarter (2026-06-30): EPS=-0.20 | Chg30d=+1.61% | Revisions=+17% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.20 | Chg30d=+3.49% | Revisions=-17% | Analysts=9
EPS current Year (2026-12-31): EPS=-0.76 | Chg30d=+0.78% | Revisions=+25% | GrowthEPS=+13.6% | GrowthRev=+95.5%
EPS next Year (2027-12-31): EPS=-0.63 | Chg30d=+1.51% | Revisions=+40% | GrowthEPS=+17.7% | GrowthRev=+201.4%
[Analyst] Revisions Ratio: +25% (up=6, down=3)